Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

IGC Relative to the S&P 500

IGC Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the India Globalization Capital, Inc. (AMEX:IGC) seasonal charts above shows that a Buy Date of January 1 and a Sell Date of March 28 has resulted in a geometric average return of 13.37% above the benchmark rate of the S&P 500 Total Return Index over the past 18 years. This seasonal timeframe has shown positive results compared to the benchmark in 10 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 18 years by an average of 45.24% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

To download IGC seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: IGC